{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:01:48Z","timestamp":1779976908749,"version":"3.53.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["RCBS20221008093243060"],"award-info":[{"award-number":["RCBS20221008093243060"]}]},{"name":"Shenzhen Medical Research Fund","award":["A2403044"],"award-info":[{"award-number":["A2403044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03935-3","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:05:28Z","timestamp":1779969928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kaempferol-based nanocarriers as a potential therapeutic strategy against drug-resistant lung cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Pouya","family":"Goleij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Khazeei Tabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana\u00e9 S.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboube","family":"Hadipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Poudineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"3935_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin 2022, 72(1).","DOI":"10.3322\/caac.21708"},{"issue":"3","key":"3935_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3935_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia. 2021;25(1):45\u201352.","journal-title":"Contemp Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"issue":"1","key":"3935_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3935_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cllc.2020.12.004","volume":"22","author":"N Prinzi","year":"2021","unstructured":"Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M. Recent advances in the management of typical and atypical lung carcinoids. Clin Lung Cancer. 2021;22(3):161\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"3935_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"YP Liu","year":"2021","unstructured":"Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021;2(3):315\u201340.","journal-title":"MedComm (2020)"},{"key":"3935_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073811","author":"F Viana Cabral","year":"2024","unstructured":"Viana Cabral F, Quilez Alburquerque J, Roberts HJ, Hasan T. Shedding light on chemoresistance: the perspective of photodynamic therapy in cancer management. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073811.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"3935_CR8","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.1080\/10408398.2022.2067121","volume":"63","author":"SP Bangar","year":"2023","unstructured":"Bangar SP, Chaudhary V, Sharma N, Bansal V, Ozogul F, Lorenzo JM. Kaempferol: a flavonoid with wider biological activities and its applications. Crit Rev Food Sci Nutr. 2023;63(28):9580\u2013604.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"3935_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1080\/10942912.2023.2205040","volume":"26","author":"M Shahbaz","year":"2023","unstructured":"Shahbaz M, Imran M, Alsagaby SA, Naeem H, Al Abdulmonem W, Hussain M, Abdelgawad MA, El-Ghorab AH, Ghoneim MM, El-Sherbiny M. Anticancer, antioxidant, ameliorative and therapeutic properties of kaempferol. Int J Food Prop. 2023;26(1):1140\u201366.","journal-title":"Int J Food Prop"},{"key":"3935_CR10","doi-asserted-by":"crossref","unstructured":"Jan R, Khan M, Asaf S, Lubna, Asif S, Kim KM. Bioactivity and Therapeutic Potential of Kaempferol and Quercetin: New Insights for Plant and Human Health. Plants (Basel) 2022, 11(19).","DOI":"10.3390\/plants11192623"},{"issue":"1","key":"3935_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22(1):169.","journal-title":"Mol Cancer"},{"key":"3935_CR12","doi-asserted-by":"crossref","unstructured":"Liang X-J, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-drug Resist Cancer 2010:467\u201388.","DOI":"10.1007\/978-1-60761-416-6_21"},{"issue":"2","key":"3935_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205\u201327.","journal-title":"Expert Opin Drug Deliv"},{"key":"3935_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2023.105705","volume":"108","author":"SM Meybodi","year":"2023","unstructured":"Meybodi SM, Rezaei P, Faraji N, Jamehbozorg K, Ashna S, Shokri F, Goleij P, Moradi S, Kashian M, Arefnezhad R. Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: new trends and future perspectives in cancer therapy. J Funct Foods. 2023;108: 105705.","journal-title":"J Funct Foods"},{"key":"3935_CR15","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"39","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagn Photodyn Ther. 2022;39:102915.","journal-title":"Photodiagn Photodyn Ther"},{"key":"3935_CR16","doi-asserted-by":"crossref","unstructured":"Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomed 2014:2539\u201355.","DOI":"10.2147\/IJN.S47129"},{"issue":"7","key":"3935_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/jpm14070723","volume":"14","author":"JB Oehler","year":"2024","unstructured":"Oehler JB, Rajapaksha W, Albrecht H. Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer. J Personalized Med. 2024;14(7):723.","journal-title":"J Personalized Med"},{"issue":"17","key":"3935_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179451","volume":"22","author":"A Ramos","year":"2021","unstructured":"Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22(17): 9451.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3935_CR19","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3935_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031853","volume":"23","author":"M Haider","year":"2022","unstructured":"Haider M, Elsherbeny A, Pittal\u00e0 V, Consoli V, Alghamdi MA, Hussain Z, Khoder G, Greish K. Nanomedicine strategies for management of drug resistance in lung cancer. Int J Mol Sci. 2022;23(3): 1853.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3935_CR21","first-page":"e1291","volume":"5","author":"FU Vaidya","year":"2022","unstructured":"Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, Pathak C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep. 2022;5(12):e1291.","journal-title":"Cancer Rep"},{"key":"3935_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-020-00568-z","volume":"18","author":"M Gong","year":"2020","unstructured":"Gong M, Li Y, Ye X, Zhang L, Wang Z, Xu X, Shen Y, Zheng C. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1\/NRF2 pathway activation. Cell Commun Signal. 2020;18:1\u201311.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3935_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41392-022-01200-x","volume":"7","author":"Z Niu","year":"2022","unstructured":"Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Therapy. 2022;7(1):353.","journal-title":"Signal Transduct Target Therapy"},{"key":"3935_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2021.07.006","volume":"159","author":"WCM Dempke","year":"2021","unstructured":"Dempke WCM, Reck M. KEAP1\/NRF2 (NFE2L2) mutations in NSCLC\u2013fuel for a superresistant phenotype? Lung Cancer. 2021;159:10\u20137.","journal-title":"Lung Cancer"},{"issue":"1","key":"3935_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","volume":"26","author":"Y Jeong","year":"2020","unstructured":"Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H. Role of KEAP1\/NFE2L2 mutations in the chemotherapeutic response of patients with non\u2013small cell lung cancer. Clin Cancer Res. 2020;26(1):274\u201381.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3935_CR26","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s12276-023-01091-0","volume":"55","author":"DH Shin","year":"2023","unstructured":"Shin DH, Jo JY, Choi M, Kim K-H, Bae Y-K, Kim SS. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Exp Mol Med. 2023;55(10):2220\u201337.","journal-title":"Exp Mol Med"},{"issue":"2","key":"3935_CR27","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141\u201360.","journal-title":"Cancer Drug Resist"},{"key":"3935_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512222","author":"N Bou Antoun","year":"2023","unstructured":"Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241512222.","journal-title":"Int J Mol Sci"},{"key":"3935_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020136","author":"YF Lin","year":"2022","unstructured":"Lin YF, Liu JJ, Chang YJ, Yu CS, Yi W, Lane HY, Lu CH. Predicting anticancer drug resistance mediated by mutations. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15020136.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3935_CR30","doi-asserted-by":"crossref","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, Ahmed H, Rahman N, Nainu F, Wahyudin E et al. Multidrug resistance in cancer: Understanding molecular mechanisms, Immunoprevention and therapeutic approaches. Front Oncol 2022, 12.","DOI":"10.3389\/fonc.2022.891652"},{"issue":"1","key":"3935_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, Sun Y, Peng A. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"key":"3935_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000645","author":"MA Mishan","year":"2021","unstructured":"Mishan MA, Khazeei Tabari MA, Mahrooz A, Bagheri A. Role of micrornas in the anticancer effects of the flavonoid luteolin: a systematic review. Eur J Cancer Prev. 2021. https:\/\/doi.org\/10.1097\/CEJ.0000000000000645.","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"3935_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"3935_CR34","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3390\/cancers13174363","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 2021;13(17):4363.","journal-title":"Cancers (Basel)"},{"key":"3935_CR35","doi-asserted-by":"publisher","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"L-y Li","year":"2021","unstructured":"Li L-y, Guan Y-d, Chen X-s, Yang J-m, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol. 2021;11:629266.","journal-title":"Front Pharmacol"},{"issue":"21","key":"3935_CR36","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3390\/cancers14215305","volume":"14","author":"K Khaddour","year":"2022","unstructured":"Khaddour K, Felipe Fernandez M, Khabibov M, Garifullin A, Dressler D, Topchu I, Patel JD, Weinberg F, Boumber Y. The prognostic and therapeutic potential of DNA damage repair pathway alterations and homologous recombination deficiency in lung cancer. Cancers (Basel). 2022;14(21):5305.","journal-title":"Cancers (Basel)"},{"key":"3935_CR37","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1007\/s11033-021-06314-z","volume":"48","author":"A Kara","year":"2021","unstructured":"Kara A, \u00d6zg\u00fcr A, Nalbanto\u011flu S, Karada\u011f A. DNA repair pathways and their roles in drug resistance for lung adenocarcinoma. Mol Biol Rep. 2021;48:3813\u201325.","journal-title":"Mol Biol Rep"},{"key":"3935_CR38","doi-asserted-by":"publisher","first-page":"49447","DOI":"10.1007\/s11356-021-15759-5","volume":"28","author":"A Elfadadny","year":"2021","unstructured":"Elfadadny A, El-Husseiny HM, Abugomaa A, Ragab RF, Mady EA, Aboubakr M, Samir H, Mandour AS, El-Mleeh A, El-Far AH. Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives. Environ Sci Pollut Res. 2021;28:49447\u201366.","journal-title":"Environ Sci Pollut Res"},{"issue":"2","key":"3935_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.dmpk.2019.12.001","volume":"35","author":"M Takano","year":"2020","unstructured":"Takano M, Higa S, Furuichi Y, Naka R, Yumoto R. Suppression of P-glycoprotein by cigarette smoke extract in human lung-derived A549\/P-gp cells. Drug Metab Pharmacokinet. 2020;35(2):214\u20139.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3935_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104161","author":"Y Guo","year":"2024","unstructured":"Guo Y, Ashrafizadeh M, Tambuwala MM, Ren J, Orive G, Yu G. P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding rnas, drugs and nanomodulators. Drug Discov Today. 2024. https:\/\/doi.org\/10.1016\/j.drudis.2024.104161.","journal-title":"Drug Discov Today"},{"key":"3935_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194783","author":"C Riganti","year":"2019","unstructured":"Riganti C, Contino M. New strategies to overcome resistance to chemotherapy and immune system in cancer. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20194783.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3935_CR42","first-page":"566","volume":"22","author":"A Kara","year":"2022","unstructured":"Kara A, \u00d6zg\u00fcr A, Tekin \u015e, Tutar Y. Computational analysis of drug resistance network in lung adenocarcinoma. Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents). 2022;22(3):566\u201378.","journal-title":"Anti-Cancer Agents Med Chem (Formerly Curr Med Chemistry-Anti-Cancer Agents)"},{"issue":"3","key":"3935_CR43","doi-asserted-by":"publisher","first-page":"768","DOI":"10.21037\/tlcr-19-547","volume":"9","author":"P Chen","year":"2020","unstructured":"Chen P, Kuang P, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, Ye L, Yu F. Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure. Transl Lung Cancer Res. 2020;9(3):768.","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"3935_CR44","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.3390\/cancers14194562","volume":"14","author":"A Ashrafi","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MC, Deese AR, Zhang L. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers. 2022;14(19):4562.","journal-title":"Cancers"},{"issue":"9","key":"3935_CR45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.","journal-title":"Cell Death Dis"},{"key":"3935_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010190","author":"S Muto","year":"2023","unstructured":"Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, et al. Wnt\/\u03b2-catenin signaling and resistance to immune checkpoint inhibitors: from non-Small-Cell lung cancer to other cancers. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11010190.","journal-title":"Biomedicines"},{"issue":"1","key":"3935_CR47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/s12967-024-05380-8","volume":"22","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Westover D, Tang Z, Liu Y, Sun J, Sun Y, Zhang R, Wang X, Zhou S, Hesilaiti N, et al. Wnt\/\u03b2-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer. J Translational Med. 2024;22(1):565.","journal-title":"J Translational Med"},{"issue":"12","key":"3935_CR48","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol. 2021;16(12):2002\u201315.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3935_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/cbin.10995","volume":"42","author":"L Hua","year":"2018","unstructured":"Hua L, Zhu G, Wei J. Microrna-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy. Cell Biol Int. 2018;42(9):1240\u20139.","journal-title":"Cell Biol Int"},{"issue":"14","key":"3935_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147594","volume":"23","author":"M Konoshenko","year":"2022","unstructured":"Konoshenko M, Lansukhay Y, Krasilnikov S, Laktionov P. Micrornas as predictors of lung-cancer resistance and sensitivity to cisplatin. Int J Mol Sci. 2022;23(14): 7594.","journal-title":"Int J Mol Sci"},{"key":"3935_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00239-2","volume":"6","author":"Y Gu","year":"2025","unstructured":"Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, Yang L, Wang H. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed. 2025;6(1):2","journal-title":"Mol Biomed"},{"key":"3935_CR52","doi-asserted-by":"crossref","unstructured":"Goleij P, Tabari MAK, Khandan M, Poudineh M, Rezaee A, Sadreddini S, Sanaye PM, Khan H, Larsen DS, Daglia M. Genistein in focus: Pharmacological effects and immune pathway modulation in cancer. Naunyn Schmiedebergs Arch Pharmacol 2024:1\u201315.","DOI":"10.1007\/s00210-024-03647-x"},{"issue":"null","key":"3935_CR53","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.2147\/IJN.S209773","volume":"14","author":"S Govindaraju","year":"2019","unstructured":"Govindaraju S, Roshini A, Lee M-H, Yun K. Kaempferol conjugated gold nanoclusters enabled efficient for anticancer therapeutics to A549 lung cancer cells. Int J Nanomed. 2019;14(null):5147\u201357.","journal-title":"Int J Nanomed"},{"issue":"10","key":"3935_CR54","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.21037\/tlcr-22-235","volume":"11","author":"JP Casta\u00f1eda-Gonz\u00e1lez","year":"2022","unstructured":"Casta\u00f1eda-Gonz\u00e1lez JP, Chaves JJ, Parra-Medina R. Multiple mutations in the EGFR gene in lung cancer: a systematic review. Transl Lung Cancer Res. 2022;11(10):2148\u201363.","journal-title":"Transl Lung Cancer Res"},{"key":"3935_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104295","volume":"196","author":"A Ferro","year":"2024","unstructured":"Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, Bonanno L. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024;196: 104295.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3935_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4143\/crt.2023.461","volume":"56","author":"Y Jeon","year":"2024","unstructured":"Jeon Y, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. First-line alectinib vs. brigatinib in advanced non-small cell lung cancer with ALK rearrangement: real-world data. Cancer Res Treat. 2024;56(1):61\u20139.","journal-title":"Cancer Res Treat"},{"key":"3935_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","volume":"354","author":"AL Onugwu","year":"2023","unstructured":"Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA, Emeh P, Nnamani PO, Attama AA, Khutoryanskiy VV. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release. 2023;354:465\u201388.","journal-title":"J Control Release"},{"key":"3935_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155949","volume":"134","author":"P Goleij","year":"2024","unstructured":"Goleij P, Sanaye PM, Alam W, Zhang J, Tabari MAK, Filosa R, Jeandet P, Cheang WS, Efferth T, Khan H. Unlocking daidzein\u2019s healing power: present applications and future possibilities in phytomedicine. Phytomedicine. 2024;134: 155949.","journal-title":"Phytomedicine"},{"issue":"1","key":"3935_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12951-023-01768-8","volume":"21","author":"J-Y Park","year":"2023","unstructured":"Park J-Y, Lee G-H, Yoo KH, Khang D. Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs. J Nanobiotechnol. 2023;21(1):12.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3935_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.annonc.2020.11.010","volume":"32","author":"J Jee","year":"2021","unstructured":"Jee J, Li BT. Expanding the nanotherapeutic toolbox for non-small-cell lung cancer. Ann Oncol. 2021;32(1):9\u201311.","journal-title":"Ann Oncol"},{"key":"3935_CR61","doi-asserted-by":"publisher","first-page":"115306","DOI":"10.1016\/j.addr.2024.115306","volume":"209","author":"Y Choi","year":"2024","unstructured":"Choi Y, Seok SH, Yoon HY, Ryu JH, Kwon IC. Advancing cancer immunotherapy through siRNA-based gene Silencing for immune checkpoint Blockade. Adv Drug Deliv Rev. 2024;209:115306.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"3935_CR62","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s12551-022-00962-6","volume":"14","author":"M Grin","year":"2022","unstructured":"Grin M, Suvorov N, Ostroverkhov P, Pogorilyy V, Kirin N, Popov A, Sazonova A, Filonenko E. Advantages of combined photodynamic therapy in the treatment of oncological diseases. Biophys Rev. 2022;14(4):941\u201363.","journal-title":"Biophys Rev"},{"issue":"10","key":"3935_CR63","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.7150\/jca.24577","volume":"9","author":"H Zhang","year":"2018","unstructured":"Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9(10):1773\u201381.","journal-title":"J Cancer"},{"issue":"6","key":"3935_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","volume":"30","author":"YR Murciano-Goroff","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507\u201319.","journal-title":"Cell Res"},{"issue":"28","key":"3935_CR65","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al. Five-year overall survival for patients with advanced non\u2013small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518\u201327.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3935_CR66","doi-asserted-by":"publisher","first-page":"354","DOI":"10.21037\/atm-22-4218","volume":"11","author":"A Olivares-Hern\u00e1ndez","year":"2023","unstructured":"Olivares-Hern\u00e1ndez A, Del Gonz\u00e1lez E, Tamayo-Velasco \u00c1, Figuero-P\u00e9rez L, Zhilina-Zhilina S, Fonseca-S\u00e1nchez E, Miramontes-Gonz\u00e1lez JP. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review. Ann Transl Med. 2023;11(10):354.","journal-title":"Ann Transl Med"},{"issue":"5","key":"3935_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/14712598.2019.1592155","volume":"19","author":"G Hamilton","year":"2019","unstructured":"Hamilton G, Rath B. Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opin Biol Ther. 2019;19(5):423\u201332.","journal-title":"Expert Opin Biol Ther"},{"key":"3935_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","volume":"4","author":"M Yuan","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.","journal-title":"Signal Transduct Target Ther"},{"key":"3935_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194562","author":"A Ashrafi","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14194562.","journal-title":"Cancers (Basel)"},{"key":"3935_CR70","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.eujim.2020.101163","volume":"37","author":"I Charid","year":"2020","unstructured":"Charid I, Kessler M, Darb-Esfahani S, Zemojtel T, Abobaker S, Tyuarets S, Schrauwen S, Atmani-Kilani D, Benaida-Debbache N, Sch\u00e4fer R, et al. Pretreatment with methanolic extract of pistacia lentiscus L. increases sensitivity to DNA damaging drugs in primary high-grade serous ovarian cancer cells. Eur J Integr Med. 2020;37:101163.","journal-title":"Eur J Integr Med"},{"issue":"24","key":"3935_CR71","doi-asserted-by":"publisher","first-page":"8864","DOI":"10.3390\/molecules27248864","volume":"27","author":"MY Qattan","year":"2022","unstructured":"Qattan MY, Khan MI, Alharbi SH, Verma AK, Al-Saeed FA, Abduallah AM, Al Areefy AA. Therapeutic importance of kaempferol in the treatment of cancer through the modulation of cell signalling pathways. Molecules. 2022;27(24):8864.","journal-title":"Molecules"},{"issue":"1","key":"3935_CR72","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-020-01756-y","volume":"39","author":"J-F Liu","year":"2020","unstructured":"Liu J-F, Chen P-C, Chang T-M, Hou C-H. Monocyte chemoattractant protein-1 promotes cancer cell migration via c-Raf\/MAPK\/AP-1 pathway and MMP-9 production in osteosarcoma. J Exp Clin Cancer Res. 2020;39(1):254.","journal-title":"J Exp Clin Cancer Res"},{"key":"3935_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109086","volume":"117","author":"X Wang","year":"2019","unstructured":"Wang X, Yang Y, An Y, Fang G. The mechanism of anticancer action and potential clinical use of Kaempferol in the treatment of breast cancer. Biomed Pharmacother. 2019;117: 109086.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"3935_CR74","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.3390\/nu13113750","volume":"13","author":"F Crocetto","year":"2021","unstructured":"Crocetto F, di Zazzo E, Buonerba C, Aveta A, Pandolfo SD, Barone B, Trama F, Caputo VF, Scafuri L, Ferro M, et al. Kaempferol, myricetin and fisetin in prostate and bladder cancer: a systematic review of the literature. Nutrients. 2021;13(11):3750.","journal-title":"Nutrients"},{"key":"3935_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030845","author":"R Kubina","year":"2021","unstructured":"Kubina R, Iriti M, Kaba\u0142a-Dzik A. Anticancer potential of selected flavonols: fisetin, kaempferol, and Quercetin on head and neck cancers. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13030845.","journal-title":"Nutrients"},{"key":"3935_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174251","volume":"907","author":"X Wang","year":"2021","unstructured":"Wang X, Zhu J, Yan H, Shi M, Zheng Q, Wang Y, Zhu Y, Miao L, Gao X. Kaempferol inhibits benign prostatic hyperplasia by resisting the action of androgen. Eur J Pharmacol. 2021;907: 174251.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3935_CR77","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1080\/10942912.2023.2205040","volume":"26","author":"M Shahbaz","year":"2023","unstructured":"Shahbaz M, Imran M, Alsagaby SA, Naeem H, Al Abdulmonem W, Hussain M, Abdelgawad MA, El-Ghorab AH, Ghoneim MM, El-Sherbiny M, et al. Anticancer, antioxidant, ameliorative and therapeutic properties of kaempferol. Int J Food Prop. 2023;26(1):1140\u201366.","journal-title":"Int J Food Prop"},{"key":"3935_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.fitote.2016.10.008","volume":"115","author":"V Zabela","year":"2016","unstructured":"Zabela V, Sampath C, Oufir M, Moradi-Afrapoli F, Butterweck V, Hamburger M. Pharmacokinetics of dietary kaempferol and its metabolite 4-hydroxyphenylacetic acid in rats. Fitoterapia. 2016;115:189\u201397.","journal-title":"Fitoterapia"},{"issue":"3","key":"3935_CR79","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/17425255.3.3.389","volume":"3","author":"Z Liu","year":"2007","unstructured":"Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol. 2007;3(3):389\u2013406.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3935_CR80","doi-asserted-by":"publisher","first-page":"155090","DOI":"10.1016\/j.phymed.2023.155090","volume":"121","author":"R Wang","year":"2023","unstructured":"Wang R, Deng Z, Zhu Z, Wang J, Yang X, Xu M, Wang X, Tang Q, Zhou Q, Wan X, et al. Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway. Phytomedicine. 2023;121:155090.","journal-title":"Phytomedicine"},{"key":"3935_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108700","volume":"697","author":"C Fouzder","year":"2021","unstructured":"Fouzder C, Mukhuty A, Kundu R. Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells. Arch Biochem Biophys. 2021;697: 108700.","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"3935_CR82","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.7150\/jca.88038","volume":"15","author":"M Guan","year":"2024","unstructured":"Guan M, Xu W, Bai H, Geng Z, Yu Z, Li H, Liu T. Potential mechanisms underlying inhibition of xenograft lung cancer models by kaempferol: modulation of gut microbiota in activating immune cell function. J Cancer. 2024;15(5):1314\u201327.","journal-title":"J Cancer"},{"key":"3935_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27144553","author":"Y Ma","year":"2022","unstructured":"Ma Y, Liu J, Cui X, Hou J, Yu F, Wang J, Wang X, Chen C, Tong L. Hyaluronic acid modified nanostructured lipid carrier for targeting delivery of Kaempferol to NSCLC: preparation, optimization, characterization, and performance evaluation in vitro. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27144553.","journal-title":"Molecules"},{"issue":"3","key":"3935_CR84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.joim.2023.03.009","volume":"21","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang Y-b, Che X-w, Wang H, Wang W. Junctional adhesion molecule-like protein as a novel target for Kaempferol to ameliorate lung adenocarcinoma. J Integr Med. 2023;21(3):268\u201376.","journal-title":"J Integr Med"},{"issue":"9","key":"3935_CR85","first-page":"63","volume":"19","author":"J Preeti, Akhtar","year":"2023","unstructured":"Preeti, Akhtar J, Verma A, Badruddeen, Khan MI, Ahmad M. Kaempferol: topical applications and nanoformulations in the treatment of diseases. Curr Bioact Compd. 2023;19(9):63\u201373.","journal-title":"Curr Bioact Compd"},{"key":"3935_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1318-y","volume":"20","author":"M Colombo","year":"2019","unstructured":"Colombo M, de Lima Melchiades G, Michels LR, Figueir\u00f3 F, Bassani VL, Teixeira HF, Koester LS. Solid dispersion of kaempferol: formulation development, characterization, and oral bioavailability assessment. AAPS PharmSciTech. 2019;20:1\u20139.","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"3935_CR87","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2174\/1389201017666160127110609","volume":"17","author":"S Qian","year":"2016","unstructured":"Qian S, Ramamurthy Y, Candasamy S, Md M, Kumar SH, Meka RS. Production, characterization and evaluation of Kaempferol nanosuspension for improving oral bioavailability. Curr Pharm Biotechnol. 2016;17(6):549\u201355.","journal-title":"Curr Pharm Biotechnol"},{"issue":"10","key":"3935_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108630","volume":"24","author":"A Almatroudi","year":"2023","unstructured":"Almatroudi A, Allemailem KS, Alwanian WM, Alharbi BF, Alrumaihi F, Khan AA, Almatroodi SA, Rahmani AH. Effects and mechanisms of kaempferol in the management of cancers through modulation of inflammation and signal transduction pathways. Int J Mol Sci. 2023;24(10): 8630.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3935_CR89","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s13346-023-01357-0","volume":"13","author":"W He","year":"2023","unstructured":"He W, Zhang J, Ju J, Wu Y, Zhang Y, Zhan L, Li C, Wang Y. Preparation, characterization, and evaluation of the antitumor effect of Kaempferol nanosuspensions. Drug Delivery Translational Res. 2023;13(11):2885\u2013902.","journal-title":"Drug Delivery Translational Res"},{"key":"3935_CR90","doi-asserted-by":"publisher","first-page":"114820","DOI":"10.1016\/j.biopha.2023.114820","volume":"163","author":"GK Subbaraj","year":"2023","unstructured":"Subbaraj GK, Masoodi T, Yasam SK, Chandrashekar K, Kulanthaivel L, Shaik NA, Hashem S, Akil ASA, Bhat AA. Anti-angiogenic effect of nano-formulated water soluble Kaempferol and combretastatin in an in vivo chick Chorioallantoic membrane model and HUVEC cells. Biomed Pharmacother. 2023;163:114820.","journal-title":"Biomed Pharmacother"},{"issue":"50","key":"3935_CR91","doi-asserted-by":"publisher","first-page":"35127","DOI":"10.1039\/D3RA06537E","volume":"13","author":"HT Oanh","year":"2023","unstructured":"Oanh HT, Thu NTH, Van Hanh N, Hoang MH, Hien HTM. Co-encapsulated astaxanthin and kaempferol nanoparticles: fabrication, characterization, and their potential synergistic effects on treating non-alcoholic fatty liver disease. RSC Adv. 2023;13(50):35127\u201336.","journal-title":"RSC Adv"},{"issue":"2","key":"3935_CR92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discovery"},{"key":"3935_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103938","volume":"78","author":"C Caro","year":"2022","unstructured":"Caro C, Pourmadadi M, Eshaghi MM, Rahmani E, Shojaei S, Paiva-Santos AC, Rahdar A, Behzadmehr R, Garc\u00eda-Mart\u00edn ML, D\u00edez-Pascual AM. Nanomaterials loaded with Quercetin as an advanced tool for cancer treatment. J Drug Deliv Sci Technol. 2022;78: 103938.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"3935_CR94","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1039\/C7FO00508C","volume":"8","author":"M Huang","year":"2017","unstructured":"Huang M, Su E, Zheng F, Tan C. Encapsulation of flavonoids in liposomal delivery systems: the case of quercetin, Kaempferol and Luteolin. Food Funct. 2017;8(9):3198\u2013208.","journal-title":"Food Funct"},{"issue":"4","key":"3935_CR95","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/10717544.2012.679710","volume":"19","author":"AP Landi-Librandi","year":"2012","unstructured":"Landi-Librandi AP, Caleiro Seixas Azzolini AE, de Oliveira CA, Lucisano-Valim YM. Inhibitory activity of liposomal flavonoids during oxidative metabolism of human neutrophils upon stimulation with immune complexes and phorbol ester. Drug Deliv. 2012;19(4):177\u201387.","journal-title":"Drug Deliv"},{"issue":"27","key":"3935_CR96","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.2174\/1381612826666200526145706","volume":"26","author":"M Liu","year":"2020","unstructured":"Liu M, Wen J, Sharma M. Solid lipid nanoparticles for topical drug delivery: mechanisms, dosage form perspectives, and translational status. Curr Pharm Design. 2020;26(27):3203\u201317.","journal-title":"Curr Pharm Design"},{"issue":"2","key":"3935_CR97","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1166\/jbn.2009.1026","volume":"5","author":"K Sutthanut","year":"2009","unstructured":"Sutthanut K, Lu X, Jay M, Sripanidkulchai B. Solid lipid nanoparticles for topical administration of Kaempferia parviflora extracts. J Biomed Nanotechnol. 2009;5(2):224\u201332.","journal-title":"J Biomed Nanotechnol"},{"issue":"6","key":"3935_CR98","doi-asserted-by":"publisher","first-page":"14591","DOI":"10.33263\/BRIAC116.1459114601","volume":"11","author":"T Aghazadeh","year":"2021","unstructured":"Aghazadeh T, Bakhtiari N, Rad IA, Ramezani F. Formulation of Kaempferol in nanostructured lipid carriers (NLCs): a delivery platform to sensitization of MDA-MB468 breast cancer cells to Paclitaxel. Biointerface Res Appl Chem. 2021;11(6):14591\u2013601.","journal-title":"Biointerface Res Appl Chem"},{"key":"3935_CR99","doi-asserted-by":"crossref","unstructured":"Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomed 2015:1001\u201318.","DOI":"10.2147\/IJN.S56932"},{"key":"3935_CR100","doi-asserted-by":"publisher","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","volume":"12","author":"A Gagliardi","year":"2021","unstructured":"Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:601626.","journal-title":"Front Pharmacol"},{"issue":"19","key":"3935_CR101","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.3390\/nano12193426","volume":"12","author":"P Heydari Foroushani","year":"2022","unstructured":"Heydari Foroushani P, Rahmani E, Alemzadeh I, Vossoughi M, Pourmadadi M, Rahdar A, D\u00edez-Pascual AM. Curcumin sustained release with a hybrid chitosan-silk fibroin nanofiber containing silver nanoparticles as a novel highly efficient antibacterial wound dressing. Nanomaterials. 2022;12(19):3426.","journal-title":"Nanomaterials"},{"issue":"1","key":"3935_CR102","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/bm401812r","volume":"15","author":"C Garofalo","year":"2014","unstructured":"Garofalo C, Capuano G, Sottile R, Tallerico R, Adami R, Reverchon E, Carbone E, Izzo L, Pappalardo D. Different insight into amphiphilic PEG-PLA copolymers: influence of macromolecular architecture on the micelle formation and cellular uptake. Biomacromolecules. 2014;15(1):403\u201315.","journal-title":"Biomacromolecules"},{"key":"3935_CR103","doi-asserted-by":"crossref","unstructured":"Bala I, Hariharan S, Kumar MR. PLGA nanoparticles in drug delivery: the state of the Art. Crit Reviews\u2122 Therapeutic Drug Carrier Syst 2004, 21(5).","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20"},{"issue":"12","key":"3935_CR104","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3390\/pharmaceutics13122086","volume":"13","author":"I Kazmi","year":"2021","unstructured":"Kazmi I, Al-Abbasi FA, Afzal M, Altayb HN, Nadeem MS, Gupta G. Formulation and evaluation of Kaempferol loaded nanoparticles against experimentally induced hepatocellular carcinoma: in vitro and in vivo studies. Pharmaceutics. 2021;13(12):2086.","journal-title":"Pharmaceutics"},{"key":"3935_CR105","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3389\/fbioe.2020.00990","volume":"8","author":"X Hu","year":"2020","unstructured":"Hu X, Zhang Y, Ding T, Liu J, Zhao H. Multifunctional gold nanoparticles: a novel nanomaterial for various medical applications and biological activities. Front Bioeng Biotechnol. 2020;8:990.","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"3935_CR106","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.procbio.2015.08.003","volume":"50","author":"BS Raghavan","year":"2015","unstructured":"Raghavan BS, Kondath S, Anantanarayanan R, Rajaram R. Kaempferol mediated synthesis of gold nanoparticles and their cytotoxic effects on MCF-7 cancer cell line. Process Biochem. 2015;50(11):1966\u201376.","journal-title":"Process Biochem"},{"key":"3935_CR107","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.saa.2012.12.076","volume":"106","author":"S Bhuvanasree","year":"2013","unstructured":"Bhuvanasree S, Harini D, Rajaram A, Rajaram R. Rapid synthesis of gold nanoparticles with Cissus quadrangularis extract using microwave irradiation. Spectrochim Acta Part A Mol Biomol Spectrosc. 2013;106:190\u20136.","journal-title":"Spectrochim Acta Part A Mol Biomol Spectrosc"},{"key":"3935_CR108","doi-asserted-by":"publisher","first-page":"194308921350947","DOI":"10.1177\/1943089213509474","volume":"1","author":"M Khoobchandani","year":"2013","unstructured":"Khoobchandani M, Zambre A, Katti K, Lin C-H, Katti KV. Green nanotechnology from brassicaceae: development of broccoli phytochemicals\u2013encapsulated gold nanoparticles and their applications in nanomedicine. Int J Green Nanatechnol. 2013;1:1943089213509474.","journal-title":"Int J Green Nanatechnol"},{"key":"3935_CR109","doi-asserted-by":"crossref","unstructured":"Govindaraju S, Roshini A, Lee M-H, Yun K. Kaempferol conjugated gold nanoclusters enabled efficient for anticancer therapeutics to A549 lung cancer cells. Int J Nanomed 2019:5147\u201357.","DOI":"10.2147\/IJN.S209773"},{"issue":"19","key":"3935_CR110","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3748\/wjg.v25.i19.2279","volume":"25","author":"OO Ogunwobi","year":"2019","unstructured":"Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019;25(19):2279.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3935_CR111","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12645-022-00132-z","volume":"13","author":"NM Alyami","year":"2022","unstructured":"Alyami NM, Alyami HM, Almeer R. Using green biosynthesized kaempferol-coated sliver nanoparticles to inhibit cancer cells growth: an in vitro study using hepatocellular carcinoma (HepG2). Cancer Nanotechnol. 2022;13(1):26.","journal-title":"Cancer Nanotechnol"},{"key":"3935_CR112","unstructured":"Ahmed H. The Challenges Behind Scaling Up Nanomaterials. In.: AZoNano; 2022."},{"key":"3935_CR113","doi-asserted-by":"crossref","unstructured":"Muthu MS, Wilson B. Challenges posed by the scale-up of nanomedicines. In., vol. 7: Taylor & Francis; 2012: 307\u2013309.","DOI":"10.2217\/nnm.12.3"},{"issue":"6","key":"3935_CR114","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","volume":"15","author":"R Paliwal","year":"2014","unstructured":"Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech. 2014;15(6):1527\u201334.","journal-title":"AAPS PharmSciTech"},{"key":"3935_CR115","doi-asserted-by":"crossref","unstructured":"Hassan D, Sani A, Medina DI. Limitations of nanocarriers such as cell and tissue toxicity, genotoxicity, Scale-Up of nanomaterials. In: Khan FA, editor. Nano drug delivery for cancer therapy: principles and practices. Springer; 2024. p. 149\u201371.","DOI":"10.1007\/978-981-99-6940-1_8"},{"issue":"5","key":"3935_CR116","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/21691401.2016.1192040","volume":"45","author":"S Ilk","year":"2017","unstructured":"Ilk S, Saglam N, \u00d6zgen M. Kaempferol loaded lecithin\/chitosan nanoparticles: preparation, characterization, and their potential applications as a sustainable antifungal agent. Artif Cells Nanomed Biotechnol. 2017;45(5):907\u201316.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"17","key":"3935_CR117","first-page":"1798","volume":"42","author":"LIU Jin-li","year":"2022","unstructured":"Jin-li LIU, Yu-fei MA, Jia-fu HOU, Lei T. Preparation of Kaempferol loaded solid lipid nanoparticles and its anti-non-small-cell carcinoma effect\u2009<\u2009i\u2009>\u2009in vitro. Chin J Hosp Pharm. 2022;42(17):1798\u2013803.","journal-title":"Chin J Hosp Pharm"},{"issue":"14","key":"3935_CR118","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.3390\/molecules27144553","volume":"27","author":"Y Ma","year":"2022","unstructured":"Ma Y, Liu J, Cui X, Hou J, Yu F, Wang J, Wang X, Chen C, Tong L. Hyaluronic acid modified nanostructured lipid carrier for targeting delivery of Kaempferol to NSCLC: preparation, optimization, characterization, and performance evaluation in vitro. Molecules. 2022;27(14):4553.","journal-title":"Molecules"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03935-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:02:46Z","timestamp":1779973366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-03935-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3935"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03935-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"Not appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appropriate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}